|
|
Notes Limit - 3 per order
|
Description
About Avodart
Benign Prostatic Hyperplasia ( BPH ) is one of the most common health problems in older men. BPH often begins after age 50 and can progress and worsen as men age. More than half of men over the age of 60 experience BPH, and by age 80 nearly 80% of men have the disease.
Avodart, a second-generation 5 alpha-reductase inhibitor, is the first and only medicine to inhibit both the type 1 and type 2 enzymes responsible for the conversion of testosterone to DHT (dihydrotestosterone), the primary cause of prostate growth. Advodart's dual inhibition decreases levels of DHT by 90 percent at two weeks and 93 percent at two years.
|
|
